Jane Street’s AnaptysBio ANAB Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | – | Sell |
-86,038
| Closed | -$5.22M | – | 11457 |
|
|
2026
Q1 | $4.77M | Buy |
86,038
+1,591
| +2% | +$85.6K | ﹤0.01% | 3591 |
|
|
2025
Q4 | $4.09M | Sell |
84,447
-96,665
| -53% | -$3.77M | ﹤0.01% | 3546 |
|
|
2025
Q3 | $5.55M | Buy |
181,112
+136,444
| +305% | +$3.13M | ﹤0.01% | 3276 |
|
|
2025
Q2 | $992K | Buy |
+44,668
| New | +$935K | ﹤0.01% | 5638 |
|
|
2025
Q1 | – | Sell |
-44,613
| Closed | -$591K | – | 9353 |
|
|
2024
Q4 | $591K | Sell |
44,613
-8,544
| -16% | -$207K | ﹤0.01% | 6420 |
|
|
2024
Q3 | $1.78M | Buy |
53,157
+9,795
| +23% | +$335K | ﹤0.01% | 4728 |
|
|
2024
Q2 | $1.09M | Buy |
43,362
+4,674
| +12% | +$109K | ﹤0.01% | 5611 |
|
|
2024
Q1 | $871K | Buy |
38,688
+8,581
| +29% | +$203K | ﹤0.01% | 5656 |
|
|
2023
Q4 | $645K | Buy |
30,107
+4,438
| +17% | +$76.5K | ﹤0.01% | 6331 |
|
|
2023
Q3 | $461K | Buy |
+25,669
| New | +$490K | ﹤0.01% | 6415 |
|
|
2023
Q2 | – | Sell |
-11,957
| Closed | -$260K | – | 8620 |
|
|
2023
Q1 | $260K | Buy |
11,957
+2,310
| +24% | +$56.1K | ﹤0.01% | 7423 |
|
|
2022
Q4 | $299K | Buy |
9,647
+1,244
| +15% | +$35.1K | ﹤0.01% | 7032 |
|
|
2022
Q3 | $214K | Sell |
8,403
-29,277
| -78% | -$686K | ﹤0.01% | 8064 |
|
|
2022
Q2 | $765K | Buy |
+37,680
| New | +$835K | ﹤0.01% | 5974 |
|
|
2021
Q1 | – | Sell |
-16,288
| Closed | -$350K | – | 9041 |
|
|
2020
Q4 | $350K | Sell |
16,288
-2,958
| -15% | -$71.8K | ﹤0.01% | 6195 |
|
|
2020
Q3 | $284K | Buy |
+19,246
| New | +$347K | ﹤0.01% | 5950 |
|
|
2020
Q1 | – | Sell |
-36,709
| Closed | -$596K | – | 5253 |
|
|
2019
Q4 | $596K | Buy |
36,709
+29,288
| +395% | +$693K | ﹤0.01% | 3474 |
|
|
2019
Q3 | $260K | Buy |
7,421
+3,786
| +104% | +$180K | ﹤0.01% | 4326 |
|
|
2019
Q2 | $205K | Buy |
+3,635
| New | +$262K | ﹤0.01% | 4667 |
|
|
2018
Q4 | – | Sell |
-8,791
| Closed | -$877K | – | 4881 |
|
|
2018
Q3 | $877K | Buy |
+8,791
| New | +$729K | ﹤0.01% | 2920 |
|
|
2018
Q2 | – | Sell |
-8,842
| Closed | -$920K | – | 4927 |
|
|
2018
Q1 | $920K | Buy |
8,842
+5,050
| +133% | +$569K | ﹤0.01% | 2754 |
|
|
2017
Q4 | $382K | Buy |
+3,792
| New | +$279K | ﹤0.01% | 3491 |
|
Other funds holding ANAB
EC
TCM
AAA
S
WP
6CM
Jane Street's ANAB Position: Q2 2026 in Review
Jane Street sold out of AnaptysBio (ANAB) in Q2 2026, closing a stake of 86,038 shares — an estimated $5.22M sold.
Jane Street first reported a position in ANAB in Q4 2017 and held it in 22 quarters. The position peaked at $5.55M in Q3 2025. 210 funds tracked by Wall St. Rank hold ANAB as of Q2 2026.
- Jane Street reported no remaining AnaptysBio position as of Q2 2026 after selling out during the quarter.
- Jane Street sold 86,038 AnaptysBio shares in Q2 2026, an estimated $5.22M.
- Jane Street first reported a position in AnaptysBio in Q4 2017 and held it in 22 quarters.
- Jane Street's AnaptysBio position peaked at $5.55M in Q3 2025.
- 210 funds tracked by Wall St. Rank held AnaptysBio as of Q2 2026.
Based on Jane Street's 13F filing for Q2 2026, filed 14 Aug 2026.